A detailed history of Marshall Wace, LLP transactions in Immunocore Holdings PLC stock. As of the latest transaction made, Marshall Wace, LLP holds 248,654 shares of IMCR stock, worth $7.76 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
248,654
Previous 217,951 14.09%
Holding current value
$7.76 Million
Previous $14.2 Million 40.52%
% of portfolio
0.01%
Previous 0.02%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$33.78 - $63.75 $1.04 Million - $1.96 Million
30,703 Added 14.09%
248,654 $8.43 Million
Q1 2024

May 15, 2024

BUY
$60.14 - $75.36 $13.1 Million - $16.4 Million
217,951 New
217,951 $14.2 Million
Q3 2023

Nov 14, 2023

SELL
$49.5 - $66.6 $156,667 - $210,788
-3,165 Reduced 3.56%
85,639 $4.44 Million
Q2 2023

Aug 14, 2023

BUY
$48.54 - $61.64 $3.14 Million - $3.99 Million
64,684 Added 268.18%
88,804 $5.32 Million
Q1 2023

May 15, 2023

SELL
$46.12 - $65.71 $288,711 - $411,344
-6,260 Reduced 20.61%
24,120 $1.19 Million
Q4 2022

Feb 14, 2023

BUY
$45.51 - $65.08 $284,892 - $407,400
6,260 Added 25.95%
30,380 $1.73 Million
Q4 2021

Feb 14, 2022

BUY
$27.58 - $40.0 $665,229 - $964,800
24,120 New
24,120 $826,000

Others Institutions Holding IMCR

About Immunocore Holdings plc


  • Ticker IMCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,897,100
  • Market Cap $1.37B
  • Description
  • Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in ...
More about IMCR
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.